Tiverton Asset Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Tiverton Asset Management’s Portfolio CNCE Stock Details CNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-77,782	Closed	-$1.78M	–	526
2018 Q1	$1.78M	Buy	+77,782	New	+$1.73M	0.12%	122

Other funds holding CNCE

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Tiverton Asset Management's CNCE Position: Q2 2018 in Review

Tiverton Asset Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q2 2018, closing a stake of 77,782 shares — an estimated $1.78M sold.

Tiverton Asset Management first reported a position in CNCE in Q1 2018 and held it in 1 quarter. The position peaked at $1.78M in Q1 2018. 120 funds tracked by Wall St. Rank hold CNCE as of Q2 2018.

Tiverton Asset Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Tiverton Asset Management sold 77,782 Concert Pharmaceuticals, Inc. shares in Q2 2018, an estimated $1.78M.
Tiverton Asset Management first reported a position in Concert Pharmaceuticals, Inc. in Q1 2018 and held it in 1 quarter.
Tiverton Asset Management's Concert Pharmaceuticals, Inc. position peaked at $1.78M in Q1 2018.
120 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q2 2018.

Based on Tiverton Asset Management's 13F filing for Q2 2018, filed 10 Aug 2018.